Decaestecker K - Search Results

1

The First Entirely 3D-Printed Training Model for Robot-assisted Kidney Transplantation: The RAKT Box.

Campi R, Pecoraro A, Vignolini G, Spatafora P, Sebastianelli A, Sessa F, Li Marzi V, Territo A, Decaestecker K, Breda A, Serni S; RAKT Box Collaborators; European Association of Urology EAU Young Academic Urologists Kidney Transplantation working group the EAU Robotic Urology Section Robot-assisted Kidney Transplantation Working Group. Campi R, et al. Among authors: decaestecker k. Eur Urol Open Sci. 2023 Jun 2;53:98-105. doi: 10.1016/j.euros.2023.05.012. eCollection 2023 Jul. Eur Urol Open Sci. 2023. PMID: 37304228 Free PMC article.

2

Development of a pre- and postoperative physical activity promotion program integrated in the electronic health system of patients with bladder cancer (The POPEYE study): An intervention mapping approach.

Rammant E, Deforche B, Van Hecke A, Verhaeghe S, Van Ruymbeke B, Bultijnck R, Van Hemelrijck M, Fox L, Pieters R, Decaestecker K, Fonteyne V. Rammant E, et al. Among authors: decaestecker k. Eur J Cancer Care (Engl). 2021 Mar;30(2):e13363. doi: 10.1111/ecc.13363. Epub 2020 Nov 17. Eur J Cancer Care (Engl). 2021. PMID: 33205552

3

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.

Verghote F, Poppe L, Verbeke S, Dirix P, Albersen M, De Meerleer G, Berghen C, Ost P, Villeirs G, De Visschere P, De Man K, De Maeseneer D, Rottey S, Van Praet C, Decaestecker K, Fonteyne V. Verghote F, et al. Among authors: decaestecker k. BMC Cancer. 2021 Oct 18;21(1):1113. doi: 10.1186/s12885-021-08861-x. BMC Cancer. 2021. PMID: 34663254 Free PMC article. Clinical Trial.

4

Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome.

Fonteyne V, Lumen N, Ost P, Van Praet C, Vandecasteele K, De Gersem Ir W, Villeirs G, De Neve W, Decaestecker K, De Meerleer G. Fonteyne V, et al. Among authors: decaestecker k. Radiother Oncol. 2013 Nov;109(2):229-34. doi: 10.1016/j.radonc.2013.08.006. Epub 2013 Sep 7. Radiother Oncol. 2013. PMID: 24016677

5

A novel mutation c.118delA in exon 1 of the androgen receptor gene resulting in complete androgen insensitivity syndrome within a large family.

Decaestecker K, Philibert P, De Baere E, Hoebeke P, Kaufman JM, Sultan C, T'Sjoen G. Decaestecker K, et al. Fertil Steril. 2008 May;89(5):1260.e3-1260.e7. doi: 10.1016/j.fertnstert.2007.04.057. Epub 2007 Aug 21. Fertil Steril. 2008. PMID: 17714709 Free article.

6

Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.

Poelaert F, Fonteyne V, Ost P, De Troyer B, Decaestecker K, De Meerleer G, De Visschere P, Claeys T, Dhondt B, Lumen N. Poelaert F, et al. Among authors: decaestecker k. Strahlenther Onkol. 2017 Jun;193(6):444-451. doi: 10.1007/s00066-016-1094-5. Epub 2017 Jan 18. Strahlenther Onkol. 2017. PMID: 28101585 English.

7

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.

De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L, Goetghebeur E, De Meerleer G, Lumen N, Fonteyne V, De Maeseneer D, Ost P. De Wolf K, et al. Among authors: decaestecker k. Radiat Oncol. 2017 Sep 22;12(1):157. doi: 10.1186/s13014-017-0893-x. Radiat Oncol. 2017. PMID: 28938918 Free PMC article. Clinical Trial.

8

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.

Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, Delrue L, Billiet I, Duthoy W, Junius S, Huysse W, Lumen N, Ost P. Decaestecker K, et al. BMC Cancer. 2014 Sep 15;14:671. doi: 10.1186/1471-2407-14-671. BMC Cancer. 2014. PMID: 25223986 Free PMC article. Clinical Trial.

9

Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy.

Van Praet C, Ost P, Lumen N, De Meerleer G, Vandecasteele K, Villeirs G, Decaestecker K, Fonteyne V. Van Praet C, et al. Among authors: decaestecker k. Radiother Oncol. 2013 Nov;109(2):222-8. doi: 10.1016/j.radonc.2013.08.021. Epub 2013 Sep 7. Radiother Oncol. 2013. PMID: 24016674

10

Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer.

Bultijnck R, Van de Caveye I, Rammant E, Everaert S, Lumen N, Decaestecker K, Fonteyne V, Deforche B, Ost P. Bultijnck R, et al. Among authors: decaestecker k. BJU Int. 2018 Apr;121(4):610-618. doi: 10.1111/bju.14086. Epub 2018 Jan 10. BJU Int. 2018. PMID: 29194928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

161 results

Search Page